Population Pharmacokinetics and Exposure-Response with Durvalumab Plus Platinum-Etoposide in ES-SCLC: Results from CASPIAN

被引：0

作者：

Zheng, Y. ^{[1
]}

Jin, D. ^{[1
]}

Guan, Y. ^{[1
]}

Ozguroglu, M. ^{[2
]}

Trukhin, D. ^{[3
]}

Poltoratskiy, A. ^{[4
]}

Chen, Y. ^{[5
]}

Havel, L. ^{[6
]}

Hochmair, M. ^{[7
]}

Paz-Ares, L. ^{[8
,9
]}

Jiang, H. ^{[10
]}

Armstrong, J. ^{[11
]}

Chen, C. ^{[1
]}

Liu, Y. H. ^{[10
]}

Roskos, L. ^{[1
]}

机构：

[1] Astrazeneca, San Francisco, CA USA

[2] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Istanbul, Turkey

[3] Odessa Reg Oncol Dispensary, Odessa, Ukraine

[4] Petrov Res Inst Oncol, St Petersburg, Russia

[5] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA

[6] Charles Univ Prague, Fac Med 1, Thomayer Hosp, Prague, Czech Republic

[7] Krankenhaus Nord, Karl Landsteiner Inst Lung Res & Pulm Oncol, Vienna, Austria

[8] Univ Complutense, Hosp Univ 12 Octubre, H120 Cnio Lung Canc Unit, Madrid, Spain

[9] Ciberonc, Madrid, Spain

[10] Astrazeneca, Gaithersburg, MD USA

[11] Astrazeneca, Cambridge, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

CASPIAN; population pharmacokinetics; Durvalumab;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P48.21

引用

页码：S508 / S508

页数：1

共 50 条

[31] Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
Paz-Ares, L.
Chen, Y.
Reinmuth, N.
Hotta, K.
Trukhin, D.
Statsenko, G.
Hochmair, M. J.
Ozguroglu, M.
Ji, J. H.
Voitko, O.
Poltoratskiy, A.
Ponce, S.
Verderame, F.
Havel, L.
Bondarenko, I.
Kazarnowicz, A.
Losonczy, G.
Conev, N. V.
Armstrong, J.
Byrne, N.
Shire, N.
Jiang, H.
Goldman, J.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S7 - S8
[32] Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
Chen, Yuanbin
Paz-Ares, Luis
Reinmuth, Niels
Garassino, Marina Chiara
Statsenko, Galina
Hochmair, Maximilian J.
Oezgueroglu, Mustafa
Verderame, Francesco
Havel, Libor
Losonczy, Gyoergy
Conev, Nikolay, V
Hotta, Katsuyuki
Ji, Jun Ho
Spencer, Stuart
Dalvi, Tapashi
Jiang, Haiyi
Goldman, Jonathan W.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 3 (06):
[33] EQ-5D UTILITY ESTIMATES FROM THE CASPIAN TRIAL OF DURVALUMAB plus CARBOPLATIN/CISPLATIN plus ETOPOSIDE VS. CARBOPLATIN/CISPLATIN plus ETOPOSIDE IN FIRST LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
Johal, S.
Fischer, C.
Genestier, V
Brannman, L.
VALUE IN HEALTH, 2022, 25 (01) : S210 - S210
[34] First-line Treatment with Durvalumab and Platinum-Etoposide Combination for Patients with ED-SCLC: Exploratory Analyzes based on the Disease Extent in CASPIAN
Bischoff, H.
Reinmuth, N.
Dvorkin, M.
Garassino, M. C.
Trukhin, D.
Hochmair, M. J.
Ozguroglu, M.
Havel, L.
Goldman, J. W.
Chen, Y.
Losonczy, G.
Spinnato, F.
Conev, N., V
Bar, J.
Broadhurst, H.
Byrne, N.
Jiang, H.
Paz-Ares, L.
Grohe, C.
PNEUMOLOGIE, 2021, 75 : S17 - S17
[35] Financial toxicity of front-line platinum etoposide plus atezolizumab versus durvalumab in extensive-stage small-cell (ES-SCLC) lung cancer.
Harrison, Bradley
Keith, Nicole
Verbyla, Allison
Mileham, Kathryn Finch
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (28) : 23 - 23
[36] Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Paz-Ares, Luis
Dvorkin, Mikhail
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowicz, Andrzej
Losonczy, Gyorgy
Conev, Nikolay V.
Armstrong, Jon
Byrne, Natalie
Shire, Norah
Jiang, Haiyi
Goldman, Jonathan W.
Batagelj, Emilio
Casarini, Ignacio
Pastor, Anea Viviana
Sena, Susana Noemi
Zarba, Juan Jose
Burghuber, Otto
Hartl, Sylvia
Hochmair, Maximilian J.
Lamprecht, Bernd
Studnicka, Michael
Schlittler, Luis Alberto
de Oliveira, Fabricio Augusto Martinelli
Calabrich, Aknar
Girotto, Gustavo Colagiovanni
Dos Reis, Peo
Gorini, Carlos Fausto Nino
De Marchi, Peo Rafael Martins
Baldotto, Clarissa Serodio da Rocha
Sette, Claudia
Zukin, Mauro
Conev, Nikolay V.
Dudov, Assen
Ilieva, Rumyana
Koynov, Krassimir
Krasteva, Rositsa
Tonev, Ivan
LANCET, 2019, 394 (10212): : 1929 - 1939
[37] Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Goldman, Jonathan W.
Dvorkin, Mikhail
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian J.
Ozguroglu, Mustafa
Ji, Jun Ho
Garassino, Marina Chiara
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowicz, Andrzej
Losonczy, Gyorgy
Conev, Nikolay V.
Armstrong, Jon
Byrne, Natalie
Thiyagarajah, Piruntha
Jiang, Haiyi
Paz-Ares, Luis
LANCET ONCOLOGY, 2021, 22 (01): : 51 - 65
[38] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
Katsuyuki Hotta
Makoto Nishio
Haruhiro Saito
Isamu Okamoto
Yasuharu Nakahara
Hidetoshi Hayashi
Manabu Hayama
Peter Laud
Haiyi Jiang
Luis Paz-Ares
Koichi Azuma
International Journal of Clinical Oncology, 2021, 26 : 1073 - 1082
[39] First-line durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: CASPIAN Japan subgroup analysis
Hotta, Katsuyuki
Nishio, Makoto
Saito, Haruhiro
Okamoto, Isamu
Nakahara, Yasuharu
Hayashi, Hidetoshi
Hayama, Manabu
Laud, Peter
Jiang, Haiyi
Paz-Ares, Luis
Azuma, Koichi
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (06) : 1073 - 1082
[40] Durvalumab (D) ± Tremelimumab (T) plus Platinum Etoposide (EP) in 1L extensive-stage (ES) SCLC: Characteristics of Patients with Long-term Survival in the CASPIAN Study
Reinmuth, N.
Goldman, J. W.
Garassino, M. C.
Chen, Y.
Hotta, K.
Hochmair, M. J.
Ozguroglu, M.
Ji, J. H.
Statsenko, G.
Voitko, O.
Conev, N., V
Bondarenko, I.
Mann, H.
Xie, M.
Shrestha, Y.
Chugh, P.
Dalvi, T.
Paz-Ares, L.
Alt, J.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 101 - 102

← 1 2 3 4 5 →